New Airline CO2 Emissions Monitor From Cirium Reveals 40% Less Fuel Burnt From Flights Flown Globally In 2021
10.11.2021 11:00:00 EET | Business Wire | Press release
Cirium, the aviation analytics company, today launched its Global Aircraft Emissions Monitor, providing a highly accurate measure of CO2 emissions and fuel consumption from flights flown globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005600/en/
Cirium data shows the global flights tracked and fuel burn Jan-Nov 2021 versus 2019. (Graphic: Business Wire)
New insights from Cirium show that airlines have burnt 40% less fuel from flights in 2021 year-to-date compared to the same period in 2019.
The reduction in flight-produced carbon emissions is attributed to the drop in flights worldwide because of the dramatic impact that COVID-19 had on air travel. Flights tracked year-to-date are 29% down versus 2019.
The fuel burn has increased as domestic and international flights have started to return but not as much as expected compared to 2019—before the pandemic. The airlines have been flying their aircraft far fewer hours and prioritizing more efficient aircraft.
“To achieve the aggressive targets for aviation to reach net zero emissions by 2050, a thorough understanding is needed of all elements of an aircraft used for flights and the exact flight operations,” said Jeremy Bowen, CEO at Cirium.
“Cirium’s Global Aircraft Emissions Monitor boasts data of the highest quality and validity. The need for greater sustainability is clear and Cirium is committed to supporting the industry’s decision-making based on accurate carbon emissions tracking.”
The uniqueness of the product derives from the data, which is obtained from the widest and deepest data warehouse in the aviation industry. No other independent source can provide calculations based on the same blended data sets. The Monitor’s custom data calculations are based on hundreds of flight and aircraft variables for maximum accuracy. These variables include actual flight and taxi times, cabin configuration, aircraft operating empty weight, assumed cargo tonnage, aircraft/engine type, winglet equipage, aircraft age and more.
Tests conducted on the Global Aircraft Emissions Monitor have validated its accuracy in the order of 1%.
The Global Aircraft Emissions Monitor includes customized options for CO2 emissions and fuel consumption. It applies complete profiles of actual flights and aircraft, which are fused with block fuel burn models.
While aviation has reduced its emissions overall this year, travel is recovering, with Cirium forecasts projecting for global recovery to 2019 levels potentially by 2023. Cirium’s Fleet Forecast also predicts that based on the flight capacity of the increasing fleet to be in service by 2039, fuel burn may reach 485 million tons. This equates to 1,530 million tons of CO2 emissions, excluding any initiatives for sustainable aviation fuels (SAF) or offsetting.
Carbon emissions and fuel consumption from flights are increasingly becoming the centre focus for all airlines, airports aviation finance, aircraft manufacturers, air traffic management, government, and fuel providers.
The comprehensiveness of the Cirium Global Aircraft Emissions Monitor will enable organizations to track emissions as a measure of efficiency, understand aspects of total cost of ownership, understand the profile of a current operator, gain a better understanding of the climate impact, benchmark the competition, and create fuel demand models.
Find out more at https://cirium.com/EmissionsMonitor .
-End-
For further information please visit https://www.cirium.com and follow Cirium updates via LinkedIn and Twitter.
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005600/en/
Contact information
For media enquiries please contact:
Mike Arnot, Juliett Alpha via cirium@juliettalpha.com
or the Cirium media team at media@cirium.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease2.5.2026 00:28:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meeting the evolving needs of patients with myeloproliferative neoplasms (MPNs) and GVHD,” said Bill Meury, Chief Executive Officer, Incyte. “Jakafi XR offers appropriate patients and physicians a once-daily option, expanding choice without changing the well-
Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 19:08:00 EEST | Press release
A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines were switched off and everyday life took center stage. The night also celebrated the start of the new partnership between Barilla and the Visa Cash App Racing Bulls (VCARB) Formula 1® Team, a meeting of
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 13:07:00 EEST | Press release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 02:17:00 EEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
Grindr Nominates Three New Directors to Its Board of Directors1.5.2026 00:16:00 EEST | Press release
Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced the nomination of Rob Solomon, Lisa Gersh, and Fadi Hanna to stand for election to its Board of Directors at the Annual Meeting of Shareholders on June 2, 2026. Rob Solomon is a deeply seasoned technology CEO and operator in consumer internet and marketplaces. He has held CEO and COO roles at scaled platforms including GoFundMe, Groupon, and Kayak-predecessor SideStep, and is currently CEO of leading electric aviation company H55. Lisa Gersh is a CEO and long-tenured public company director with deep experience across consumer brands, media, and commerce. She has served on the Hasbro (NASDAQ: HAS) board since 2010 and has led businesses including Oxygen Media, GOOP, and Alexander Wang. Fadi Hanna is Chief Risk Officer at Bloomberg L.P., overseeing enterprise risk across the organization. He previously worked at J.P. Morgan and has served on the board of Immigration Equality. “Over the last few years, we bu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
